-
Trump expected to name intel chief Clayton as AI czar: reports
-
New rallies urged in France as protests disrupt over 730 schools
-
Argentina unveils passports-for-investment scheme
-
Djokovic survives China Open scare, Sabalenka starts strong
-
Brazil election debate chaos sparks censorship row
-
King Charles to evoke colonial 'darkest days' on Caribbean tour
-
England's Carse charged by cricket body over nightclub incident
-
Tesla shares jump after global car sales top estimates
-
Amazon vows $1 bn for data center towns, decries 'myths'
-
DR Congo Ebola outbreak killed more than 4,000: official figures
-
Oil prices drop on G7 fuel release, US jobs data boosts stocks
-
Djokovic survives China Open scare against wildcard world no. 104
-
G7 agrees deal to ease global energy supply concerns
-
Lula, Bolsonaro trade blows in final scramble for votes in Brazil
-
Spain's government dealt blow as lawmakers reject housing bills
-
New clashes erupt as protests disrupt over 560 French schools
-
Food, medicine shortages deepen in Russian-occupied Oleshky
-
NY governor vows to close loophole after alleged Cornell gang rape
-
Man City whistleblower Rui Pinto facing 'dire consequences' - lawyers
-
Ethiopia Tigray rebels pushed back as regional tensions spike
-
Russia 'tearing Kyiv apart', mayor says, as strikes paralyse traffic
-
Stocks rise, yields fall as US job numbers disappoint
-
Taiwan boxer Lin wins Games gold as Japan edge North Korea on penalties
-
Man City verdict a 'big topic' for England players, says Tuchel
-
Japan tame North Korea to win Games gold after shootout drama
-
NY attorney general tasked with investigating alleged Cornell gang rape
-
US posts weak job growth data in September
-
China widens military footprint with Laos air base
-
Ethiopia's conflict: the regional dimension
-
G7 talks as US pressures Europe over diesel stocks
-
Life expectancy almost back to pre-Covid levels, says WHO
-
Man City launch appeal against explosive financial ruling
-
Turkey's football referee chief faces judge in graft probe
-
Swiss president to quit government
-
Verstappen goes own way to avoid the rain
-
Europe rejects US threats over diesel stocks, urges joint G7 action
-
Oil slides, bonds steady as EU addresses diesel price surge
-
Philippines tennis star Eala says 'I get overwhelmed sometimes'
-
Spain housing package at risk in parliament, as protests mount
-
Ferrari chief Vasseur has support from rival team bosses
-
Swedish Social Democrats leader to make new bid to form government
-
Pilot in flydubai attack says could not let 'all those people die'
-
North Korea calls Seoul 'despicable' after DMZ apology demand
-
Eurozone inflation hits three-year high at 3.8% in September
-
Taiwan boxer Lin wins gold as virtual taekwondo makes Games debut
-
Ancelotti says Brazil 'respects' India ahead of showdown
-
Man City face appeal deadline after explosive financial verdict
-
North Korean leader's sister calls Seoul 'despicable' after DMZ apology demand
-
Pole vault superstar Duplantis to skip indoor season
-
Germany's crisis-hit rail operator looks to AI future
Athens Bioscience Unlocks Automated Citation Tracking and High-Impact Publication Insights with Bioz
PALO ALTO, CA / ACCESS Newswire / August 12, 2026 / Bioz, Inc., the platform transforming publication data into trusted product validation, announced its collaboration with Athens Bioscience, Inc., a leading provider of life science research products and solutions. Through the implementation of Bioz Badges and Bioz Content Hubs across its newly redesigned website, Athens Bioscience is providing researchers with direct access to publication-backed validation while automating the tracking of thousands of citations, including references from high-impact scientific journals.
With hundreds of SKUs and a substantial body of supporting scientific literature, Athens Bioscience recognized the importance of providing customers with direct access to publication evidence while streamlining the management of citation data. As a growing organization with a lean team, maintaining and tracking publication references manually would require significant resources and ongoing effort.
By leveraging Bioz's automated citation intelligence platform, Athens Bioscience now provides researchers with instant access to product-specific publication data directly on its website. Bioz continuously identifies, organizes, and updates citations, allowing researchers to explore validated use cases and supporting evidence without leaving the product experience.
"We've been extremely happy with Bioz," said Benjamin Newland, Chief Executive Officer of Athens Bioscience. "Citations are incredibly important to our business, particularly when it comes to tracking high-impact publications that feature our products. Bioz gives us visibility into that data while eliminating the manual effort that would otherwise be required from our team."
The implementation coincided with a major website redesign initiative at Athens Bioscience, enabling the company to integrate publication-backed content into the customer journey from the outset. The timing allowed Bioz Badges and a Content Hub to become a foundational part of the new digital experience, helping researchers quickly evaluate products using real-world scientific evidence.
For Athens Bioscience, Bioz's automation capabilities have proven particularly valuable. With hundreds of products and thousands of references to manage, Bioz continuously updates citation data and surfaces newly published research, ensuring customers always have access to the most current validation available.
"Rolling out Bioz as part of our new website project was a great experience and excellent timing for our team," added Newland. "Bioz has become an invaluable extension of our team, helping us manage a growing volume of publication data while allowing us to stay focused on our core priorities.. Bioz has also become an important resource for helping us showcase the scientific impact of our products."
Beyond improving the customer experience, Athens Bioscience also leverages Bioz data to better understand product adoption across research applications and identify emerging scientific trends. Access to structured citation insights provides valuable intelligence that supports marketing initiatives, product strategy, and customer engagement efforts.
"Companies like Athens Bioscience have built tremendous scientific value through the research community's use of their products," said Dr. Karin Lachmi, Co-Founder and Chief Revenue Officer at Bioz. "By making publication evidence easily accessible and continuously updated, they are helping researchers make more informed decisions while maximizing the value of their scientific legacy."
About Bioz
Bioz is the world's most advanced citation-based data platform for scientific research, offering evidence-backed product ratings and recommendations to guide scientists toward the most validated products and services for their discoveries. Bioz's solutions for suppliers include Bioz Badges and Bioz Content Hubs, web-based widgets that enhance user engagement and increase sales conversion.
About Athens Bioscience, Inc.
Athens Bioscience makes the proteins that help move healthcare forward. Athens Bioscience customers use them to develop diagnostic tests, manufacture biologic medicines, and run the research that becomes tomorrow's standard of care. Founded in 1985 in Athens, Georgia, Athens Bioscience manufactures hundreds of native human and animal proteins in-house. The catalog spans serum proteins, blood fractions, enzymes, and immunoglobulins, with the lot-to-lot characterization that diagnostic and cell-culture customers require. The Athens Pure™ Immunogen Grade line sets a quality benchmark for the industry, and Athens Bioscience products have supported more than 2,700 peer-reviewed publications. IVD manufacturers, cell culture media producers, and research institutions around the world rely on Athens Bioscience products.
Helpful Links
For more information about Bioz solutions for suppliers, please reach out to [email protected].
SOURCE: Bioz, Inc.
View the original press release on ACCESS Newswire
M.Fischer--AMWN